NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
5 Top Biotech Stocks To Watch In July 2022
02:30pm, Thursday, 30'th Jun 2022
Amid choppy markets, could there be potential in these top biotech stocks?
Why Global Blood Therapeutics Trended Upward Today
07:27pm, Wednesday, 29'th Jun 2022 The Motley Fool
It started enrolling patients in a promising new clinical trial.
Why Global Blood Therapeutics Trended Upward Today
03:27pm, Wednesday, 29'th Jun 2022
It started enrolling patients in a promising new clinical trial.
Global Blood Therapeutics: Powerhouse Of The Future
06:31pm, Tuesday, 21'st Jun 2022
In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2022
02:02pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2022
Guerbet reçoit l’approbation de l’EMA de son nom de marque Elucirem® pour Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet reçoit l’approbation de l’EMA de son nom de marque Elucirem® pour Gadopiclenol.
Guerbet erhält EMA-Zulassung für seinen Markennamen EluciremTM (Gadopiclenol)
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet erhält EMA-Zulassung für seinen Markennamen EluciremTM (Gadopiclenol)
Guerbet riceve dall'EMA l'approvazione del marchio EluciremTM per il Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet riceve dall'EMA l'approvazione del marchio EluciremTM per il Gadopiclenol.
Guerbet ha recibido la aprobación de la EMA de EluciremTM como nombre comercial para Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet ha recibido la aprobación de la EMA de EluciremTM como nombre comercial para Gadopiclenol.
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol.
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
07:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year
7 No-Brainer Biotech Stocks to Add to Your Buy List
09:58am, Thursday, 09'th Jun 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first
Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
03:23pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
12:48pm, Tuesday, 07'th Jun 2022
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
